NYSE$XRN
Global Medical REIT Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported a strong second quarter with significant revenue growth and strategic acquisitions.
Global Medical REIT reported a strong second quarter in 2021, marked by a 28% year-over-year increase in rental revenue, driven by portfolio growth. The company completed $71 million in acquisitions during the quarter and maintained a high portfolio occupancy rate of 99.1%.
- Rental revenue increased by 28% year-over-year, reaching $28.2 million.
- Net income attributable to common stockholders totaled $2.6 million, or $0.04 per diluted share.
- Completed seven acquisitions for an aggregate purchase price of $71 million.
- Portfolio occupancy remained high at 99.1% with a Rent Coverage Ratio of 4.4x.
Headline financials
Revenue & EPS history
Global Medical REIT · Revenue · Quarterly
$28.3M
Forward guidance
Global Medical REIT is confident in its ability to continue growing cash flow and creating value for stockholders through strategic acquisitions and portfolio management.
Tailwinds
- Continued ability to source and acquire high-quality medical facilities at attractive yields.
- Amendment of credit facility increasing available capacity and improving cost of capital.
- Strong portfolio occupancy and rent coverage ratios.
- Successful completion of acquisitions year-to-date.
- Reduced leverage as a result of equity issuances.
Headwinds
- Competitive market conditions.
- Dependence on tenants' financial health and ability to meet lease obligations.
- Risks associated with integrating new properties into the portfolio.
- Potential for increased interest rates impacting borrowing costs.
- Uncertainty regarding the timing and successful completion of pending acquisitions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+0.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.1%
Avg return
30 days after
56%
22 / 39 earnings
Positive
+7.3%
Q4 2016
Best reaction
-9.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.2% | -4.2% | — | |
| Q4 2025 | -1.6% | -2.6% | -13.2% | |
| Q3 2025 | +1.8% | +3.2% | +1.7% | |
| Q1 2025 | -9.8% | -11.7% | -17.0% | |
| Q4 2024 | +3.8% | +4.4% | +3.1% | |
| Q3 2024 | -2.6% | -3.6% | -7.4% | |
| Q2 2024 | -1.8% | -0.3% | +1.0% | |
| Q1 2024 | +3.4% | +4.8% | +8.4% | |
| Q4 2023 | -5.6% | -2.7% | -5.7% | |
| Q3 2023 | -1.8% | -0.8% | +11.7% | |
| Q2 2023 | +3.5% | +4.8% | -1.5% | |
| Q1 2023 | +0.8% | +1.8% | +1.9% | |
| Q4 2022 | -4.0% | -1.2% | -13.0% | |
| Q3 2022 | -0.9% | +0.2% | +12.3% | |
| Q2 2022 | -0.5% | -1.3% | -11.0% | |
| Q1 2022 | -5.3% | -11.9% | -12.5% | |
| Q4 2021 | -3.2% | -2.2% | +1.9% | |
| Q3 2021 | +1.6% | +1.0% | -2.5% | |
| Q2 2021 | -0.7% | -0.2% | +3.7% | |
| Q1 2021 | -1.2% | +1.0% | +5.2% | |
| Q4 2020 | +1.6% | +3.9% | +0.2% | |
| Q3 2020 | +2.0% | +1.4% | +7.2% | |
| Q2 2020 | +4.8% | +11.4% | +11.6% | |
| Q1 2020 | +7.0% | +9.3% | +26.0% | |
| Q4 2019 | +4.7% | -7.2% | -41.1% | |
| Q3 2019 | +2.3% | +9.5% | +22.4% | |
| Q2 2019 | -0.7% | +1.8% | +5.0% | |
| Q1 2019 | +1.4% | +4.5% | +7.1% | |
| Q4 2018 | +0.8% | +2.6% | -2.0% | |
| Q3 2018 | +2.2% | +2.0% | +6.4% | |
| Q2 2018 | +4.3% | +6.7% | +12.2% | |
| Q1 2018 | +2.6% | -0.1% | +4.6% | |
| Q4 2017 | +5.8% | +6.3% | +3.9% | |
| Q3 2017 | +3.1% | +3.7% | -2.8% | |
| Q2 2017 | +0.7% | +2.8% | +2.8% | |
| Q1 2017 | -1.2% | +0.0% | +0.3% | |
| Q4 2016 | +7.3% | +9.3% | +17.1% | |
| Q3 2016 | -8.5% | -14.9% | -0.2% | |
| Q2 2016 | +1.1% | +2.3% | -5.0% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro